Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu and currently employs 4,959 full-time employees. The firm is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The firm is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The firm provides products and services in Japan, Europe, North America, and other regions.
Follow-Up Questions
Who is the CEO of Shionogi & Co Ltd?
Mr. Isao Teshirogi is the Chairman of the Board of Shionogi & Co Ltd, joining the firm since 2007.
What is the price performance of SGIOF stock?
The current price of SGIOF is $18.11, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Shionogi & Co Ltd?
Shionogi & Co Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Shionogi & Co Ltd market cap?
Shionogi & Co Ltd's current market cap is $15.4B
Is Shionogi & Co Ltd a buy, sell, or hold?
According to wall street analysts, 17 analysts have made analyst ratings for Shionogi & Co Ltd, including 2 strong buy, 6 buy, 9 hold, 0 sell, and 2 strong sell
